Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: A case report

David M. Marks; Matthew J. Conner; Chi Un Pae

doi:10.1016/j.pnpbp.2008.12.022

Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: A case report

David M. Marks
, Matthew J. Conner
, Chi Un Pae

Department of Psychiatry

Duke University

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	386-387
Number of pages	2
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	33
Issue number	2
DOIs	https://doi.org/10.1016/j.pnpbp.2008.12.022
State	Published - 17 Mar 2009

Bibliographical note

Funding Information:
Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea Pharmaceuticals, Wyeth Korea, Catholic Medical Center, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea Pharmaceuticals, Inc.

Access to Document

10.1016/j.pnpbp.2008.12.022

Cite this

@article{4092382c0a8c45079dcf87c97bd1feb6,

title = "Safety and antipsychotic efficacy of {"}forced{"} intramuscular olanzapine over five days: A case report",

author = "Marks, \{David M.\} and Conner, \{Matthew J.\} and Pae, \{Chi Un\}",

note = "Funding Information: Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea Pharmaceuticals, Wyeth Korea, Catholic Medical Center, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea Pharmaceuticals, Inc.",

year = "2009",

month = mar,

day = "17",

doi = "10.1016/j.pnpbp.2008.12.022",

language = "English",

volume = "33",

pages = "386--387",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days

T2 - A case report

AU - Marks, David M.

AU - Conner, Matthew J.

AU - Pae, Chi Un

N1 - Funding Information: Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea Pharmaceuticals, Wyeth Korea, Catholic Medical Center, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Janssen Pharmaceuticals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea Pharmaceuticals, Inc.

PY - 2009/3/17

Y1 - 2009/3/17

UR - https://www.scopus.com/pages/publications/60049089545

U2 - 10.1016/j.pnpbp.2008.12.022

DO - 10.1016/j.pnpbp.2008.12.022

M3 - Letter

C2 - 19166898

AN - SCOPUS:60049089545

SN - 0278-5846

VL - 33

SP - 386

EP - 387

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

IS - 2

ER -

Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: A case report

Bibliographical note

Access to Document

Other files and links

Cite this